These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 33615115)
41. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. Borkotoky S; Dey D; Hazarika Z Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937 [TBL] [Abstract][Full Text] [Related]
42. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q Front Immunol; 2022; 13():1041860. PubMed ID: 36532082 [TBL] [Abstract][Full Text] [Related]
43. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2. Jafary F; Jafari S; Ganjalikhany MR Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306 [TBL] [Abstract][Full Text] [Related]
44. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443 [TBL] [Abstract][Full Text] [Related]
45. The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2. Li HY; Gao N; Liu CY; Liu XL; Wu F; Dai N; Han J; Li QY Front Immunol; 2022; 13():918731. PubMed ID: 35874670 [TBL] [Abstract][Full Text] [Related]
46. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related]
47. Variations in cell-surface ACE2 levels alter direct binding of SARS-CoV-2 Spike protein and viral infectivity: Implications for measuring Spike protein interactions with animal ACE2 orthologs. Kazemi S; López-Muñoz AD; Hollý J; Jin L; Yewdell JW; Dolan BP bioRxiv; 2021 Oct; ():. PubMed ID: 34729559 [TBL] [Abstract][Full Text] [Related]
48. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086 [TBL] [Abstract][Full Text] [Related]
49. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587 [TBL] [Abstract][Full Text] [Related]
50. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189 [TBL] [Abstract][Full Text] [Related]
51. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984 [TBL] [Abstract][Full Text] [Related]
52. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. Hu S; Wang J; Zhang Y; Bai H; Wang C; Wang N; He L J Med Virol; 2021 May; 93(5):3143-3151. PubMed ID: 33580518 [TBL] [Abstract][Full Text] [Related]
55. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. VanPatten S; He M; Altiti A; F Cheng K; Ghanem MH; Al-Abed Y Future Med Chem; 2020 Sep; 12(18):1647-1656. PubMed ID: 32672061 [TBL] [Abstract][Full Text] [Related]
56. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A Molecules; 2021 May; 26(11):. PubMed ID: 34072087 [TBL] [Abstract][Full Text] [Related]
57. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098 [TBL] [Abstract][Full Text] [Related]
58. Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction. Xiong J; Xiang Y; Huang Z; Liu X; Wang M; Ge G; Chen H; Xu J; Zheng M; Chen L Front Chem; 2021; 9():740702. PubMed ID: 34646813 [TBL] [Abstract][Full Text] [Related]
59. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234 [TBL] [Abstract][Full Text] [Related]